Dipyridamole
Dipyridamole (dipyridamole) is a small molecule pharmaceutical. Dipyridamole was first approved as Persantine on 1986-12-22. The pharmaceutical is active against equilibrative nucleoside transporter 1. In addition, it is known to target high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B, equilibrative nucleoside transporter 4, 3',5'-cyclic-AMP phosphodiesterase 7B, and high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Dipyridamole (discontinued: Dipyridamole, Persantine)
CombinationsAspirin dipyridamole (discontinued: Aggrenox, Aspirin dipyridamole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aspirin
+
Dipyridamole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AGGRENOX | Boehringer Ingelheim | N-020884 DISCN | 1999-11-22 | 1 products, RLD |
Hide discontinued
Dipyridamole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PERSANTINE | Boehringer Ingelheim | N-012836 DISCN | 1986-12-22 | 3 products, RLD |
| IV PERSANTINE | Boehringer Ingelheim | N-019817 DISCN | 1990-12-13 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aggrenox | New Drug Application | 2016-08-06 |
| aspirin and dipyridamole | ANDA | 2023-12-26 |
| aspirin and dipyridamole extended release | ANDA | 2019-01-18 |
| aspirin and extended - release dipyridamole capsules, 25 mg / 200 mg | ANDA | 2025-01-14 |
| aspirin and extended-release dipyridamole | ANDA | 2025-04-23 |
| aspirin-dipyridamole | ANDA | 2023-05-15 |
| asprin and extended-release dipyridamole | ANDA | 2021-05-31 |
| dipyridamole | ANDA | 2025-01-08 |
| dipyridamole dipyridamole | ANDA | 2018-12-14 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
| J1245 | Injection, dipyridamole, per 10 mg |
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 14 | — | — | 1 | — | 15 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | 2 | — | 4 |
| Ischemic stroke | D000083242 | — | — | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dipyridamole |
| INN | dipyridamole |
| Description | Dipyridamole is a pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. It has a role as an adenosine phosphodiesterase inhibitor, an EC 3.5.4.4 (adenosine deaminase) inhibitor, a platelet aggregation inhibitor and a vasodilator agent. It is a member of piperidines, a pyrimidopyrimidine, a tertiary amino compound and a tetrol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 58-32-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL932 |
| ChEBI ID | 4653 |
| PubChem CID | 3108 |
| DrugBank | DB00975 |
| UNII ID | 64ALC7F90C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDE7B
PDE7B
HSP90AA1
HSP90AA1
Organism
Homo sapiens
Gene name
PDE7B
Gene synonyms
NCBI Gene ID
Protein name
cAMP-specific 3',5'-cyclic phosphodiesterase 7B
Protein synonyms
high-affinity cAMP-specific 3',5'-cyclic phosphodiesterase, rolipram-insensitive phosphodiesterase type 7
Uniprot ID
Mouse ortholog
Pde7b (29863)
cAMP-specific 3',5'-cyclic phosphodiesterase 7B (Q9QXQ1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Dipyridamole
+
Aspirin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Dipyridamole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,116 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,791 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use